Abbott has licensed exclusive global rights to Biotest’s BT-061, a novel humanised anti-CD4 antibody in Phase II development for rheumatoid arthritis and psoriasis that could become a successor to Humira® (adalimumab). The two companies will co-promote BT-061 in the five major European markets and Abbott will commercialise the drug outside these countries. Biotest will receive US$85 M upfront and could earn up to US$395 M in milestone payments as well as royalties.